Hutton E, Mozurkewich E
Institute of Medical Science - University of Toronto, Maternal Infant and Reproductive Health Research Unit, Suite 713, 790 Bay Street, Toronto, Ontario, Canada, M5G IN8.
Cochrane Database Syst Rev. 2001;2001(2):CD003092. doi: 10.1002/14651858.CD003092.
This is one of a series of reviews of methods of cervical ripening and labour induction using standardised methodology.
To determine the effects of extra-amniotic prostaglandin for third trimester cervical ripening or induction of labour.
The Cochrane Pregnancy and Childbirth Group trials register, the Cochrane Controlled Trials Register and bibliographies of relevant papers. Date of last search: December 2000.
(1) clinical trials comparing extra-amniotic prostaglandin used for third trimester cervical ripening or labour induction with placebo/no treatment or other methods listed above it on a predefined list of labour induction methods; (2) random allocation to the treatment or control group; (3) adequate allocation concealment; (4) violations of allocated management not sufficient to materially affect conclusions; (5) clinically meaningful outcome measures reported; (6) data available for analysis according to the random allocation; (7) missing data insufficient to materially affect the conclusions.
A strategy has been developed to deal with the large volume and complexity of trial data relating to labour induction. This has involved a two-stage method of data extraction. The initial data were extracted centrally, and incorporated into a series of primary reviews arranged by methods of induction of labour, following a standardised methodology.
Oxytocin was used to initiate or augment labour significantly less frequently with extra-amniotic prostaglandins when compared to placebo (relative risk 0.50, 95% confidence interval 0.38-0.66). No other findings were significant in the comparisons that were made for this review including when extra-amniotic prostaglandins were compared with other methods of cervical ripening or induction of labour. Although this could suggest that extra-amniotic prostaglandins are as effective as other agents, the findings are difficult to interpret because they are based on very small numbers and may lack the power to show a real difference.
REVIEWER'S CONCLUSIONS: The studies in this review are limited by their small sample sizes which are in many cases further divided into multiple comparison groups. The analyses resulted in most comparisons showing no significant differences, with wide confidence intervals. Although extra-amniotic prostaglandins may be as effective as other modalities in initiating labour, there is little conclusive information from this review to guide clinical practice. An adequately powered randomised controlled trial would be useful to determine if the use of extra-amniotic prostaglandins would lower the rate of caesarean section. However, in the time since these studies were undertaken the use of extra-amniotic prostaglandins has largely been replaced by other modes of prostaglandin administration.
这是一系列使用标准化方法对宫颈成熟和引产方法进行的综述之一。
确定羊膜外前列腺素用于孕晚期宫颈成熟或引产的效果。
Cochrane妊娠与分娩组试验注册库、Cochrane对照试验注册库以及相关论文的参考文献。最后检索日期:2000年12月。
(1) 临床试验,将用于孕晚期宫颈成熟或引产的羊膜外前列腺素与安慰剂/不治疗或在预定义引产方法列表中位于其上方的其他方法进行比较;(2) 随机分配至治疗组或对照组;(3) 充分的分配隐藏;(4) 违反分配管理的情况不足以实质性影响结论;(5) 报告了具有临床意义的结局指标;(6) 可根据随机分配获得用于分析的数据;(7) 缺失数据不足以实质性影响结论。
已制定一项策略来处理与引产相关的大量且复杂的试验数据。这涉及两阶段的数据提取方法。初始数据在中心进行提取,并按照标准化方法纳入一系列按引产方法安排的主要综述中。
与安慰剂相比,使用羊膜外前列腺素时,催产素启动或加强宫缩的频率显著降低(相对风险0.50,95%置信区间0.38 - 0.66)。在本次综述所做比较中,包括将羊膜外前列腺素与其他宫颈成熟或引产方法进行比较时,没有其他结果具有显著性。尽管这可能表明羊膜外前列腺素与其他药物一样有效,但这些结果难以解释,因为它们基于非常小的样本量,可能缺乏显示真正差异的效力。
本综述中的研究受样本量小的限制,在许多情况下还进一步分为多个比较组。分析结果导致大多数比较显示无显著差异,置信区间较宽。尽管羊膜外前列腺素在启动分娩方面可能与其他方式一样有效,但本次综述几乎没有确凿信息可指导临床实践。一项有足够效力的随机对照试验将有助于确定使用羊膜外前列腺素是否会降低剖宫产率。然而,自这些研究开展以来,羊膜外前列腺素的使用在很大程度上已被其他前列腺素给药方式所取代。